Here are four important observations:
1. The company entered into the agreement with CRG and certain of its affiliate funds for up to $35 million of available borrowing capacity.
2. The company will use the funds to further support its mission to develop develops surgical tools for meniscus repair.
3. Ceterix’s NovoStitch suture passer is currently being used by more than 300 U.S. physicians.
4. The NovoStitch technology can also be used in minimally invasive hip and shoulder procedures.
More articles on devices:
European orthopedic trauma market — 8 key trends
Alphatec Spine appoints Donald A. Williams to board of directors — 5 key notes
Alphtec Spine net revenue up 5% in Ql: 10 things to know
